Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

British Journal of Cancer, Published online: 20 May 2020; doi:10.1038/s41416-020-0867-xNeoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Pesantez Maria Vidal Barbara Adamo Montserrat Muñoz Patricia Galván Laura Barberá Miriam Cuatrecasas Mathias Christgen Hans Kreipe Inés Monge-Escartín Patricia Villagrasa Dolors Soy Tommaso Giarratano Maria Vittoria Dieci Pierfranco Conte Nadia Harbeck Valentina Guarneri Aleix Prat Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractBackgroundPancreatic cancer is a  devastating disease with a 5-year survival rate of 20–25%. As approximately only 20% of patients diagnosed with pancreatic cancer are initially staged as resectable, it is necessary to evaluate new therapeutic approaches. Hence, neoadjuvant (radio)chemotherapy is a promising therapeutic option , especially in patients with a borderline resectable tumor. The aim of this non-randomized, monocentric, prospective, phase II clinical study was to assess the prognostic value of functional imaging techniques, i.e., [18F]2-fluoro-2-deoxy-d-glucose positron emi...
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
Conclusion: This study reveals the existence of dysfunctional T lymphocytes with specific spatial distribution, thus opening a new dimension both conceptually and mechanistically in tumor-stroma interaction in PDAC with potential impact on the efficacy of immune-regulatory therapeutic modalities.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Authors: Bhogal RH, Pericleous S, Khan AZ Abstract Surgical options and approaches to pancreatic cancer are changing in the current era. Neoadjuvant treatment strategies for pancreatic cancer combined with the increased use of minimal access surgical techniques mean that the modern pancreatic surgeon requires mastering a number of surgical approaches with to optimally manage patients. Whilst traditional open surgery remains the most frequent approach for surgery, the specific steps during surgery may need to be modified in light of the aforementioned neoadjuvant treatments. Robotic and laparoscopic approaches to pa...
Source: Gastroenterology Research and Practice - Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research
ConclusionsPathologic complete response in pancreatic cancer is actually infrequent: high-quality studies provide a more reliable picture of neoadjuvant effects, high rates of pCR are reported in selected retrospective studies but it is overestimated.
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
Purpose of review The modalities of management of resectable pancreatic ductal adenocarcinoma (PDAC) have evolved in recent years with new practice guidelines on adjuvant chemotherapy and results of randomized phase III trials. The aim of this review is to describe the state of the art in this setting and to highlight future possible perspectives. Recent findings Resectable PDAC is the tumor without vascular contact or a limited venous contact without vein irregularity. Several pathologic and biologic robust prognostic factors such as an R0 resection defined by a margin at least 1 mm have been validated. In phase II...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research
Purpose of review Clinical-trial design, analysis, and interpretation entails the use of efficient and reliable endpoints. Statistical issues related to endpoints warrant continued attention, as they may have a substantial impact on the conduct of clinical trials and on interpretation of their results. Recent findings We review concepts and discuss recent developments related to the use of time-to-event endpoints in studies on adjuvant and neoadjuvant therapy for colon, pancreatic, and gastric adenocarcinomas. The definition of endpoints has varied to a considerable extent in these settings. Although these variations ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research
Conditions:   Locally Advanced Pancreatic Adenocarcinoma;   Chemotherapy Effect;   Borderline Resectable Pancreatic Adenocarcinoma;   Pancreatectomy Intervention:   Drug: Folfirinox Sponsors:   Oslo University Hospital;   Haukeland University Hospital;   St. Olavs Hospital;   University Hospital of North Norway;   Helse Stavanger HF Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Immunotherapy has become an essential part of cancer treatment after showing great efficacy in various malignancies. However, its effectiveness in pancreatic ductal adenocarcinoma (PDAC), especially in resecta...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Conclusion: Neoadjuvant therapy for borderline resectable and resectable pancreatic ductal adenocarcinoma with CRT facilitated R0 resection in 84% patients who underwent surgery.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Study | UK Health